: Courtois was a participating investigator in the VIRGILE study , a prospective observational cohort that evaluated the long-term effectiveness, safety, and tolerability of fingolimod in French clinical practice . The study confirmed that real-world outcomes for fingolimod were consistent with Phase III clinical trials, showing a significant reduction in annualized relapse rates.
is a prominent French neurologist whose clinical and research work has significantly advanced the understanding and treatment of neurological disorders, particularly Multiple Sclerosis (MS) . Based at the Groupe Hospitalier de la Région de Mulhouse et Sud-Alsace in Mulhouse, France, her career is defined by a commitment to improving long-term patient outcomes through real-world clinical studies and the early implementation of high-efficacy therapies. Advancing Multiple Sclerosis Treatment sylvie courtois
Sylvie's style is influenced by [influences] and is known for [unique aspects of her work]. : Courtois was a participating investigator in the